Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial.
Fiche publication
Date publication
mars 2021
Journal
Kidney360
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Agarwal R, Rossignol P, Budden J, Mayo MR, Arthur S, Williams B, White WB
Lien Pubmed
Résumé
Mineralocorticoid receptor antagonists reduce mortality in patients with heart failure with reduced ejection fraction and have become a standard of care in those with resistant hypertension (rHTN). Yet, their use is limited among patients with CKD, primarily due to hyperkalemia.
Mots clés
chronic kidney disease, chronic renal insufficiency, hyperkalemia, patiromer, resistant hypertension, spironolactone
Référence
Kidney360. 2021 Mar 25;2(3):425-434